Indication: Solid Tumors (as adjuvant)

• Promising clinical data suggests that YIV-906 could help prolong survival and improve quality of life.
• YIV-906 could become the backbone for cancer therapies – by improving the therapeutic index for a broad spectrum of cancer regimens, including immunotherapies, cell therapies, chemotherapies, and radiation.

Mechanisms of Action: Immunomodulator + Cytoprotector

• YIV-906 turns cold tumors hot and potentiates anti-tumor activity by acting as immumomodulator in the tumor microenvironment
  • priming the tumor microenvironment,
  • overcoming immune resistance,
  • enhancing innate immunity,
  • enhancing adaptive immunity
• YIV-906 helps reduce non-hematological side-effects and speed up recovery by acting as a cytoprotector in the GI by:
  • reducing intestinal inflammation,
  • promoting damaged tissue repair

Regulatory Status

• FDA has granted two Orphan Drug Designations for hepatocellular carcinoma and pancreatic cancer.

Current Clinical Trial – Completed 2025

• Enrolling hepatocellular carcinoma patients with hepatitis B (+) in a Phase 2b clinical study, in the US, Mainland China, Hong Kong, and Taiwan

Indication: Inflammatory Bowel Disease (IBD)

• YIV-906 could improve quality of life for IBD patients

Mechanisms of Action: Cytoprotector

• YIV-906 acts as a cytoprotector in the GI by:
  • reducing intestinal inflammation,
  • promoting mucosal barrier healing,
  • modulating bacteria,
  • managing pain,
  • reducing colitis pathology